glp 1 based therapies GLP-1 + Gastrin: Next gen regenerative therapy GLP-1 receptor agonists and next-generation

Seeking to amend the federal Food, Drug, and Cosmetic Act (FDCA), the bills sponsors frame the proposed legislation as essential to protect patients from untested, unapproved, and potentially dangerous mass compounded drugs. The bill was immediately referred to the House Committee on Energy and Commerce

FDA labeling notes that delayed gastric emptying may affect absorption of oral medications and that these agents are not recommended for patients with severe gastroparesis

[DOI] [PubMed] [Google Scholar] 84.Fandino J, Toba L, Gonzalez-Matias LC, et al

The larger unknown risk is that tens of millions of temporary GLP-1 users develop what is a real issue for many traditionally processed food products a sudden aversion to ultra-processed flavor profiles themselves

Andreu, J